Efficacy and Tolerance of Therapeutic Apheresis in Paediatric Neurology: a Retrospective French Multicenter Study
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 200
- 试验地点
- 1
- 主要终点
- global neurological efficacy of therapeutic apheresis as assessed
研究概览
简要总结
After developing in pediatric hematology and nephrology, therapeutic apheresis is increasingly used in pediatric neurology despite a sparse level of evidence.
There are a few retrospective series with a small number of patients, concerning mainly autoimmune diseases (encephalitis, myasthenia gravis, polyradiculoneuritis).
The objective of this work is to study therapeutic apheresis (including plasma exchange and immunoadsorption) among french neuropediatric tertiary centers and to prove that this treatment modality is effective and well tolerated in pediatric neurology diseases.
详细描述
Multicenter medical data collection :
- Montpellier
- Toulouse
- Bordeaux
- Marseille
- Nancy
- Paris Kremlin Bicêtre
- Paris Robert Debré
- Paris Necker
- Paris Trousseau
- Lyon
- Besançon
- Rennes
- Reims
- Strasbourg
- La Réunion
- Nantes
- Tours
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Retrospective
入排标准
- 年龄范围
- — 至 18 Years（Child, Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- 未提供
排除标准
- 未提供
结局指标
主要结局
global neurological efficacy of therapeutic apheresis as assessed
时间窗: through study completion, an average of 2 years
lobal neurological efficacy of therapeutic apheresis as assessed by modified rankin score Modifed Rankin score, ranging from 0 (no symptoms) to 6 (death)
次要结局
- Incidence of therapeutic apheresis adverse events as assessed(through study completion, an average of 2 years)
- Description of the therapeutic apharesis modalities(through study completion, an average of 2 years)
- Number of participitants with treatment-related adverse events(during procedures)
- Incidence of adjuvant treatments(through study completion, an average of 2 years)
- Incidence of hospitalization in intensive care(through study completion, an average of 2 years)